- Home
- LVLU vs TVRD Comparison
LVLU vs TVRD Comparison
Compare LVLU & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | TVRD |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.3M | 34.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LVLU | TVRD |
|---|---|---|
| Price | $15.34 | $3.99 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $15.00 | ★ $51.67 |
| AVG Volume (30 Days) | 26.9K | ★ 48.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $315,887,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.53 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.22 | $3.50 |
| 52 Week High | $32.32 | $43.65 |
Technical Indicators
Market Signals| Indicator | LVLU | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 51.33 | 50.38 |
| Support Level | $14.18 | $3.81 |
| Resistance Level | $32.32 | $4.45 |
| Average True Range (ATR) | 1.35 | 0.25 |
| MACD | -0.25 | 0.06 |
| Stochastic Oscillator | 48.83 | 61.97 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.